Novartis AG (NVS) annual results, year to 31 December 2021: revenue USD 42,781 million, from the 20-F
Novartis AG files a 20-F with the SEC once a year, in US dollars. In the year to 31 December 2021 it reported revenue from the sale of goods of USD 42,781 million, down 12.1% on the year before. Its profit attributable to shareholders was USD 24,021 million, up 197.6%, and diluted earnings per share USD 10.63.
The year to 31 December 2021, against the year before
| Year to | Dec 2020 † | Dec 2021 † |
|---|---|---|
| Revenue from the sale of goods | 48,659 | 42,781 |
| Cost of sales | 15,121 | 11,735 |
| Gross profit | 34,777 | 32,239 |
| Research and development | 8,980 | 8,641 |
| Selling, general and administrative | 14,197 | 12,827 |
| Operating profit | 10,152 | 10,056 |
| Profit before tax | 9,878 | 24,530 |
| Income tax | 1,807 | 1,625 |
| Profit for the year | 8,071 | 24,018 |
| Profit attributable to shareholders | 8,072 | 24,021 |
| Filing | 20-F | 20-F |
USD million, from the 20-F on the SEC's EDGAR, linked in the last row, on the IFRS tags the company filed. A line the company does not file under the standard tag is left out rather than estimated.
USD per ordinary share, as filed.
Cash flow
| Year to | Dec 2020 † | Dec 2021 † |
|---|---|---|
| Cash from operations | 13,650 | 15,071 |
| Purchase of property, plant and equipment | 1,275 | 1,066 |
| Free cash flow | 12,375 | 14,005 |
| Dividends paid | 6,987 | 7,368 |
| Filing | 20-F | 20-F |
USD million. Free cash flow is cash from operations less the purchase of property, plant and equipment, arithmetic on the two filed lines.
Balance sheet at year end
| Year to | Dec 2020 † | Dec 2021 † |
|---|---|---|
| Total assets | 127,778 | 131,795 |
| Equity attributable to shareholders | 56,598 | 67,655 |
| Cash and cash equivalents | 9,658 | 12,407 |
| Borrowings, as filed | 28,531 | 25,523 |
| Lease liabilities | 2,005 | 1,896 |
| Inventories | 7,131 | 6,666 |
| Goodwill | 29,999 | 29,595 |
| Filing | 20-F | 20-F |
USD million, at each fiscal year end.
Ratios on the filed lines
| Year to | Dec 2020 † | Dec 2021 † |
|---|---|---|
| Return on year-end equity | 14.3% | 35.5% |
| Effective tax rate | 18.3% | 6.6% |
| Filing | 20-F | 20-F |
Arithmetic on the filed lines of the same year.
Every annual report here
- Year to 31 December 2025
- Year to 31 December 2024
- Year to 31 December 2023
- Year to 31 December 2022
- Year to 31 December 2021, this page
- Year to 31 December 2020
- Year to 31 December 2019
- Year to 31 December 2018
- Year to 31 December 2017
- Year to 31 December 2016
Source
20-F for the year to 31 December 2021, filed 31 January 2024, accession 0001370368-24-000004: the filing on EDGAR. All of Novartis AG's filings: EDGAR company page. The figures are in US dollars as filed.
The same record on your computer
GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.